

DEVELOPING NON-ADDICTIVE TREATMENTS FOR DRUG ADDICTION

Addressing the billion-dollar market and high unmet need for medically-assisted detoxification of opioid-dependent persons

SALSS CONTACT

Deborah C Mash PhD
Chief Executive Officer & Founder

dmash@demerx.com
Direct 305.753.2175

DemerX Inc.
1951 NW 7th Avenue, Suite 300
Miami, FL 33136
USA

www.demerx.com

SALSS RISING STAR | 2018



DemerX, Inc. | Private Company

DemerX is a clinical stage company advancing two lead drug candidates as medication-assisted therapies for opioid addiction. Our natural product lead drug – Ibogaine – is an indole alkaloid from equatorial Africa, which blocks opioid withdrawal symptoms and drug cravings, helping addicts to transition to sobriety. The Company has developed a robust IP portfolio around Noribogaine, the principal active metabolite of Ibogaine.

OUR PRODUCTS & SERVICES

DemerX has demonstrated that a single dose of Ibogaine is sufficient to detoxify opioid-dependent persons and diminish drug cravings for extended time periods. DemerX has assessed the safety, pharmacokinetics, and pharmacodynamics of Ibogaine and Noribogaine in normal healthy volunteers and in patients with opioid abuse problems.

We plan to advance Ibogaine as a medication-assisted opioid detoxification for use in medically supervised inpatient settings. Noribogaine will be developed for office-based opioid dependent withdrawal treatment and for patient detoxification of incarcerated addicts.

Ibogaine and Noribogaine may offer advantages for patients suffering from opioid use disorder, including an increase retention in treatment, decrease in illegal opioid use, decrease in mortality, and a decrease in risk behaviors related to HIV and hepatitis C.

WHAT MAKES US UNIQUE

Opioid addiction is an unmet medical need. DemerX is advancing two drug products to address the current opioid crisis. The rise in the number of people addicted to heroin and prescription opioids is a major driving factor for fast-track development and marketing of addiction drugs.

Ibogaine and Noribogaine are non-addicting alternatives to the currently available opioid medications - Methadone and Buprenorphine that dominate the 1.2B opioid addiction market.

WHY YOU SHOULD MEET US

The Company plans to raise funds for US FDA approved clinical trials of Ibogaine and Noribogaine. We will advance the Expanded Access (Compassionate Use) of Ibogaine for patients seeking opioid detoxification under the new Patient's Right-to-Try initiative.

DemerX plans to fast track Noribogaine to a pivotal Phase 2 trial, so we are interested to speak to potential industry partners and investors.

KEY TEAM

Deborah Mash PhD

· Chief Executive Officer & Founder

· Neuroscientist, Inventor and Entrepreneur

· 25+ yrs experience in the field of addiction neurobiology and NCE development

Richard Serbin

· Executive Chairman

· Global strategy advisor and entrepreneur with credentials in pharmacy and law

· 40 yrs service as an FDA regulatory and patent attorney in the healthcare industry

John Thomas

· Chief Financial Officer

· Decades of experience in senior management in biotech and healthcare fields

Robert Reder MD

· Vice President & CMO

· Expertise at every stage of the pharma lifecycle including opioid medications

Michael Karukin PhD

· COO

· 20+ yrs pharma, CTM & REMS experience

SWEDISH
AMERICAN
LIFE SCIENCE
SUMMIT
2018